Optimizing Outcomes in Advanced Prostate Cancer
|
|
- Silvia Rice
- 5 years ago
- Views:
Transcription
1
2 Optimizing Outcomes in Advanced Prostate Cancer Module 3: Focus on Recent CRPC Guidelines and Advanced Hormone-Sensitive Disease Sébastien J. Hotte, MD, MSc (HRM), FRCPC Medical Oncologist and Head, Phase I Program, Juravinski Cancer Centre, Hamilton, Ontario Associate Professor, Dept Of Oncology, McMaster University Co-Chair, GU DSG CCO-PEBC
3 Conflict of Interest Disclosures Research funding: Oncogenex, Novartis, GSK, Amgen, Roche, Astellas, Janssen, Sanofi, Bayer Consultant/Honoraria: Novartis, Janssen, Astellas, Pfizer, GSK, Sanofi, Bayer
4 Learning Objectives Review the most recent ASCO and CUA- CUOG guidelines on the management of CRPC Discuss the recent clinical trial data on the optimal management of newly diagnosed metastatic hormonesensitive prostate cancer Discuss the role of early chemotherapy for high risk nonmetastatic hormone-sensitive prostate cancer
5 Prostate Cancer: Recent CRPC Guidelines
6
7 Androgen-Deprivation Therapy: Continuous androgen deprivation (pharmaceutical or surgical) should be continued indefinitely regardless of additional therapies Benefit: Harm: Evidence strength: Recommendation strength: Moderate Moderate Weak Moderate
8 Therapies in Addition to ADT with Demonstrated Survival & Quality-of-Life Benefits: Abiraterone acetate and Prednisone should be offered Enzalutamide should be offered Benefit: Harm: Evidence strength: Recommendation strength: Moderate Low Strong Strong
9 Therapies in Addition to ADT with Demonstrated Survival & Quality-of-Life Benefits: Radium-223 should be offered to men with bone metastases Benefit: Harm: Evidence strength: Recommendation strength: Moderate Low Strong Strong
10 Therapies in Addition to ADT with Demonstrated Survival & Quality-of-Life Benefits: Docetaxel and Prednisone should be offered Benefit: Harm: Evidence strength: Recommendation strength: Moderate Moderate Strong Moderate
11 Therapies with demonstrated survival benefit and unclear quality-of-life benefit: Cabazitaxel and Prednisone may be offered to men who experience progression with Docetaxel Benefit: Harm: Evidence strength: Recommendation strength: Moderate Moderate to high Strong Moderate
12 Therapies with quality-of-life benefit without demonstrated survival benefit: Mitoxantrone plus Prednisone may be offered Benefit: Harm: Evidence strength: Recommendation strength: Low High Weak Weak
13 Therapies with biologic activity and unknown survival or quality-of-life benefit: Antiandrogens (eg, Bicalutamide, Flutamide, Nilutamide) may be offered. (Benefit: low; harm: low; evidence strength: weak; recommendation strength: weak) Ketoconazole may be offered. (Benefit: low; harm: moderate; evidence strength: weak; recommendation strength: weak) Low-dose corticosteroid monotherapy may be offered. (Benefit: low; harm: low; evidence strength: weak; recommendation strength: weak)
14 Palliative Care Services Palliative care should be offered to all patients, particularly to those exhibiting symptoms or quality-of-life (QOL) decrements, regardless of treatment type Benefit: Harm: Evidence strength: Recommendation strength: Moderate None Moderate Strong
15
16 2015 CUA-CUOG Guideline Management of CRPC What is Castration-Resistant Prostate Cancer? disease progression despite castrate levels of testosterone and may present as either a continuous rise in serum PSA levels, progression of pre-existing disease, and/or the appearance of new metastases What does it encompass? from pts without metastases or symptoms with rising PSA despite ADT to pts with metastases and significant debilitation due to cancer symptoms
17 2015 CUA-CUOG Guideline Asymptomatic or minimally symptomatic: pain that is relieved by acetaminophen or a non-steroidal anti-inflammatory Symptomatic: require regular pain medication opioid/narcotics)* treatment
18 2015 CUA-CUOG Guideline NON-MET CRPC There is no standard of care and no approved regimen in M0 CRPC Detection of mets Pts with PSADT < 8 mos: image every 3-6 mos Pts with PSADT > 12 mos: image every 6-12 mos Imaging Commonly with bone scans, abdominal/pelvic CT and chest X-ray MRI and PET still unclear
19 2015 CUA-CUOG Guideline MET CRPC (asymptomatic or minimally symptomatic) Anti-androgen (AA) should be discontinued Introduction of, or changes to, 1st generation AA or use of Corticosteroids with or without Ketoconazole may be considered Abiraterone acetate 1000 mg/day plus Prednisone 5 mg/twice daily is recommended as first-line therapy (Level 1, Grade A). Enzalutamide 160 mg/day is recommended as first-line therapy (Level 1, Grade A). Treatment with Docetaxel 75 mg/m2 every 3 weeks plus 5 mg oral Prednisone twice daily can be offered (Level 1, Grade A).
20 2015 CUA-CUOG Guideline Met CRPC (with symptoms) Treatment with Docetaxel 75 mg/m2 every 3 weeks plus 5 mg oral Prednisone twice daily is recommended (Level 1, Grade A). Radium-223 every 4 weeks for 6 cycles is recommended in patients with pain due to bone metastases and who do not have visceral metastases (Level 1, Grade A). Abiraterone acetate 1000 mg/day plus Prednisone 5 mg twice daily or Enzalutamide 160 mg/day may be considered as first-line therapy in patients who cannot receive or refused Docetaxel (Expert opinion).
21 2015 CUA-CUOG Guideline Met CRPC (who progress after Docetaxel-based chemo) Options with survival benefit Cabazitaxel (25 mg/m 2 ) plus Prednisone (5 mg/day) (Level 1, Grade A) Abiraterone acetate (1000 mg per day) plus Prednisone (5 mg twice daily) (Level 1, Grade A) Enzalutamide (160 mg/day) (Level 1, Grade A) Radium-223 q 4 weeks for 6 cycles (Level 1 Grade A) Options with unknown survival benefit Docetaxel plus Prednisone re-exposure in patients who have had a previous favorable response to Docetaxel may be reasonable (Expert Opinion). Mitoxantrone plus Prednisone may be offered for palliative pain relief (Grade C).
22 2015 CUA-CUOG Guideline CRPC with Bone mets (includes pre/post chemo settings) Denosumab (120 mg subcutaneous) or Zoledronic acid (4 mg intravenous) every 4 weeks, along with daily calcium and vitamin D supplementation, is recommended to prevent disease-related skeletal complications (Level 1, Grade A). Treatment with Zoledronic acid should not be used in men with baseline creatinine clearance <30 ml/min. Optimal duration of Zoledronic acid and Denosumab in men with CRPC and bone metastases is undefined. The risk of ONJ appears to be related to time on bone-targeted therapy; therefore caution should be taken in using these agents more than 2 years.
23 Prostate Cancer: HSPC
24 Question Which of the following non-crpc prostate cancer patients are candidates for Docetaxel therapy? a) 68 year old man with localized, Gl 9 prostate cancer and PSA of 34 being treated with IMRT and ADT b) 71 year old man with newly diagnosed metastatic prostate cancer with 2 bone metastases on bone scan c) 63 year old man with newly diagnosed metastatic prostate cancer with liver metastases d) All of the above e) 2 and 3 f) 3 only
25 ECOG 3805 (CHAARTED): Chemo-Hormonal vs Androgen Ablation Randomized Trial in Extensive Disease 3-year OS: 69.0% vs. 52.5% 3-year OS in pts with a high extent of metastatic disease: 63.4% vs. 43.9% Patients with a high extent of metastatic disease accounted for most of the benefit in the OS from Docetaxel plus ADT NEJM August ;(8):
26 Primary Endpoint: Overall Survival A All Patients 100 Hazard ratio for death with ADT+docetaxel, 0.61 (95% CI, ) P<0.001 Patients Surviving (%) ADT+docetaxel (median overall survival, 57.6 mo) ADT alone (median overall survival, 44.0 mo) No. at Risk ADT+docetaxel ADT alone Months
27 OS by Extent of Metastatic Disease at Start of ADT High Volume 100 Hazard ratio for death with ADT+docetaxel, 0.60 (95% CI, ) P<0.001 Low Volume Patients with Low-Volume Disease 100 ADT+docetaxel (median overall survival, NR) Patients Surviving (%) ADT+docetaxel (median overall survival, 49.2 mo) ADT alone (median overall survival, 32.2 mo) Patients Surviving (%) ADT alone (median overall survival, NR) Hazard ratio for death with ADT+docetaxel, 0.60 (95% CI, ) P=0.11 No. at Risk ADT+docetaxel ADT alone Months No. at Risk ADT+docetaxel ADT alone Months In patients with high volume metastatic disease, there is a 17 month improvement in median overall survival from 32.2 months to 49.2 months. We projected 33 months alone in the ADT alone arm with collaborations of SWOG9346 team. Presented By Christopher Sweeney at 2014 ASCO Annual Meeting
28 High Volume Disease 4 bone lesions and 1 lesion in any bony structure beyond the spine/pelvis OR Visceral disease
29 GETUG-AFU 15 TRIAL DESIGN Stratification : - Prior systemic TT - Glass risk group R A N D O M I Z A T I O N Arm A Arm B ADT + Docetaxel D: 75 mg/m 2 q3 up to 9 cycles ADT alone ADT: - LHRH agonist - or maximum androgen blockade - or orchiectomy Lancet Oncology February (2);149-58
30 OVERALL SURVIVAL Median follow-up 81.3 months [ ] Low Volume High Volume Median OS ADT alone: 35.1 [ ] ADT + D: 39 [ ] HR: 0.8 [ ] p=0.35 Median OS ADT alone: NR [61.8- NR] ADT + D: 83.1 [ NR] HR: 1.0 [ ] p=0.87
31 Comparison of GETUG 15 & ECOG 3805 GETUG ECOG Total Sample Size High Volume dz 183 (47.5%) 514 (65%) Median F/U 83 months 29 months Received Post-Protocol Docetaxel Received Post-Protocol Abi or Enz ADT only Arm: 80% ADT-Doce Arm: 45% ADT only Arm: NR ADT-Doce Arm: NR ADT only Arm: 33% ADT-Doce Arm: 12% ADT only Arm: 20% ADT-Doce Arm: 33% Presented by Eric J. Small, MD Genitourinary Cancers Symposium
32 CONCLUSIONS (GETUG) PFS improved by Docetaxel in mhspc (GETUG 15 and CHAARTED) Overall survival after a median follow-up of 82.9 months: No improvement in low volume mhspc (GETUG 15/ CHAARTED) Discrepancy in OS results for high-volume mhspc Explaining the OS discrepancy: Salvage Docetaxel more frequent in GETUG-15 (80%)??? GETUG 15 underpowered in high volume mhspc? Other trials to come soon (Stampede)
33 Docetaxel and/or Zoledronic acid for hormonenaïve prostate cancer: First overall survival results from STAMPEDE (NCT ) STAMPEDE: RCT using novel multi-arm, multi-stage design for men with high-risk locally advanced or metastatic PCa starting on ADT 3 comparisons reported: Standard of care (SOC) (ADT for 3+ years), Docetaxel (75mg/m2 plus Pred), Zoledronic acid (ZA) (4mg) Primary outcome: Survival 2:1:1:1 to SOC:D:Z:D+Z with N=2,962
34 Presented By Nicholas James at 2015 ASCO Annual Meeting
35 Inclusion Criteria Newly Diagnosed: Any of: Metastatic Node-positive 2 of: Stage T3/4 PSA 40 ng/ml Gleason 8-10 All Patients: Fit for all protocol treatment Fit for follow-up WHO performance status 0-2 Written informed consent Relapsing after previous RP or RT with 1 of: PSA 4 ng/ml & rising with doubling time <6 m PSA 20 ng/ml Node positive Metastatic Full Criteria: Presented By Nicholas James at 2015 ASCO Annual Meeting
36 Outcome Measures Primary Outcome Measure: Overall Survival Secondary Outcome Measures: Failure-free survival Toxicity Quality of Life Skeletal related events Cost effectiveness FFS Definition: First line of: PSA failure Local failure Lymph node failure Distant metastases Prostate cancer death PSA Failure Definition: PSA failure 50% 24 week nadir + 50% and >4 ng/ml PSA fall of 50% Failure at t=0 Presented By Nicholas James at 2015 ASCO Annual Meeting
37 STAMPEDE: All Docetaxel & Zoldronic Acid Comparisons Presented By Nicholas James at 2015 ASCO Annual Meeting
38 Patient Characteristics 1% WHO PS 2 [s] 21% WHO PS 1 [s] 65 yr Median Age (min 40, max 84) 61% Metastatic (85% bony mets) 15% N+M0 24% N0M0 [s] [s] 98% LNRH analogues [s] 29% Planned for RT (72% of N0M0 pts) 6% Previous local therapy Balanced by arm [s] Stratification factors + hospital + NSAID/aspirin [s] Presented By Nicholas James at 2015 ASCO Annual Meeting
39 Presented By Nicholas James at 2015 ASCO Annual Meeting Docetaxel: Failure-Free Survival
40 Presented By Nicholas James at 2015 ASCO Annual Meeting Docetaxel: Survival
41 Zoledronic Acid + Docetaxel: Failure-Free Survival Presented By Nicholas James at 2015 ASCO Annual Meeting
42 Zoledronic Acid + Docetaxel: Survival Presented By Nicholas James at 2015 ASCO Annual Meeting
43 Treatment Effect by Metastatic Status: FFS Pre-Planned Analysis Presented By Nicholas James at 2015 ASCO Annual Meeting
44 Treatment Effect by Metastatic Status: Overall Survival Pre-Planned Analysis Presented By Nicholas James at 2015 ASCO Annual Meeting
45 Presented By Nicholas James at 2015 ASCO Annual Meeting Docetaxel: Survival M1 Patients
46 Grade 3+ Adverse Events Ever Reported Presented By Nicholas James at 2015 ASCO Annual Meeting
47 Presented By Nicholas James at 2015 ASCO Annual Meeting Use of Life-Prolonging Therapy for Progression
48 Conclusions Docetaxel improves survival for hormone-naïve prostate cancer Zoledronic Acid does not improve survival Adding both improves survival but offers no obvious benefit over adding just Docetaxel Multi-arm, multi-stage trials are practicable and efficient Docetaxel should be: Considered for routine practice in suitable men with newlydiagnosed metastatic disease Considered for selected men with high-risk non-metastatic disease in view of substantial prolongation of failure-free survival Presented By Nicholas James at 2015 ASCO Annual Meeting
49 How Similar are the Men Participating in these Studies? Median Age % Mets at Presentation % High Risk GETUG 64 71% 52% CHAARTED 63 75% 65% STAMPEDE 65 Most of them Unknown * High volume disease was defined as visceral metastases and/or 4 bone metastases with at least one metastasis beyond the pelvis or vertebral column These trials DO NOT represent men with slowly progressive disease who develop metastases several years after diagnosis (+/- local treatment)
50 Forest Plot of Overall Survival for the 3 Studies (Thanks to Dr. Eitan Amir) Presented By Ian Tannock at 2015 ASCO Annual Meeting
51 Recommendation #1 Men with high-risk metastatic prostate cancer, especially those presenting with metastases at or soon after diagnosis, who are judged fit to receive chemotherapy, should be offered 6 cycles of Docetaxel in addition to ADT Presented By Ian Tannock at 2015 ASCO Annual Meeting
52 Role of Chemotherapy for Localized High- Risk PC (M0) After Radiation Therapy
53 Role of chemotherapy for localized high-risk PC (M0) after radiation therapy GETUG-12 (Fizazi et al; Lancet Oncol, 2015) ADT +/- 4 cycles Docetaxel/Estramustine (N=413) RFS: 199 events: HR=0.71 ( ) OS: 91 deaths: too early STAMPEDE (Not all M0 men had RT) ADT +/- 6 cycles Docetaxel/Prednisone (N=689) RFS: 229 events; HR=0.57 ( ) OS: 93 deaths; HR=1.01 but too early
54 Presented By Howard Sandler at 2015 ASCO Annual Meeting
55 Top Accruing Sites Cross Cancer Institute 32 Tom Baker Cancer Centre 32 London Regional Cancer Program 20 McGill University 19 Ottawa Hospital Regional Cancer Centre 17 Peter MacCallum Cancer Centre 15 UT-Southwestern 15 (Others with 10 or more: Fox Chase, Christiana CCOP, Northeast RO Center, Umich, Wash U) Presented By Howard Sandler at 2015 ASCO Annual Meeting
56 RTOG 0521 Stage Gleason Score PSA Any T Stage 9 < T2 8 < R a n d o m i z e ARM 1 Androgen Suppression (24 months) + External RT (8 weeks) ARM 2 Androgen Suppression (24 months) + External RT (8 weeks) + Docetaxel beginning 4 weeks after RT (6 cycles) Presented By Howard Sandler at 2015 ASCO Annual Meeting
57 Characteristic Arm 1 and Arm 2 (N = 563) Risk Category (stratification) (%) Gleason 9, PSA 150, Any T-stage 53 Gleason 8, PSA <20, T2 21 Gleason 8, PSA , Any T-stage 10 Gleason 7, PSA , Any T-stage 16 Gleason Score, no. (%) Serum PSA, ng/ml, Median (Q1-Q3) 15 (7-34) Age, Median 66 ct3-t4 27% pn0 33% Presented By Howard Sandler at 2015 ASCO Annual Meeting
58 Conclusions For the first time, improvement in overall survival observed with (tolerable) adjuvant chemotherapy for localized, highrisk, hormone-sensitive prostate cancer Cumulative incidence of DM reduced The potential role of Docetaxel in hormone-sensitive prostate cancer is consistent with and supported by our data and other studies, such as STAMPEDED and CHAARTED. This analysis is relatively early and additional follow-up will likely be enlightening. Presented By Howard Sandler at 2015 ASCO Annual Meeting
59 Role of chemotherapy for localized high-risk PC (M0) after radiation therapy GETUG-12 (Fizazi et al; Lancet Oncol, 2015) ADT +/- 4 cycles Docetaxel/Estramustine (N=413) RFS: 199 events: HR=0.71 ( ) OS: 91 deaths: too early STAMPEDE (Not all M0 men had RT) ADT +/- 6 cycles Docetaxel/Prednisone (N=689) RFS: 229 events; HR=0.57 ( ) OS: 93 deaths; HR=1.01 but too early RTOG 0521 ADT +/- 6 cycles Docetaxel/Prednisone (N=563) RFS: 221 events: HR=0.76 ( ) OS: 102 deaths: HR=0.70 ( )
60 Recommendation #2 Men with localized M0 prostate cancer who are able to receive local treatment with radiotherapy should not be offered Docetaxel in addition to ADT This opinion might change with longer follow-up of the GETUG-12, STAMPEDE, and RTOG 0521 trials Presented By Ian Tannock at 2015 ASCO Annual Meeting
61 Question The following non-crpc prostate cancer patients are candidates for Docetaxel therapy: 68 year old man with localized, Gl 9 prostate cancer and PSA of 34 being treated with IMRT and ADT RTOG 0521: not yet but depends on how early an adopter you are, or the patient in front of you. 71 year old man with newly diagnosed metastatic prostate cancer with 2 bone mets on BS CHAARTED/GETUG suggests YES. STAMPEDE strengthens that. 63 year old man with newly diagnosed metastatic prostate cancer with liver mets CHAARTED and STAMPEDE say YES. All of the above MAYBE see above. 2 and 3 YES as of this ASCO. 3 only DEFINITELY, but from STAMPEDE, can be less advanced than this and still benefit.
62
Early Chemotherapy for Metastatic Prostate Cancer
Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,
More informationChemohormonal Therapy For Prostate Cancer. What is old, is new again!
Chemohormonal Therapy For Prostate Cancer What is old, is new again! Mount Tremblant January 20, 2017 Kala S. Sridhar MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital Head, GU Medical Oncology
More informationPerspective on endocrine and chemotherapy agents. Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr. Sternberg has received research funding for
More informationWhat will change for men with advanced prostate cancer in the next 24 months? ESO Observatory: Perspective on endocrine and chemotherapy agents
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr.Sternberg has received research funding for
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationPhilip Kantoff, MD Dana-Farber Cancer Institute
CHEMOTHERAPY FOR MCRPC Philip Kantoff, MD Dana-Farber Cancer Institute Harvard Medical School 1 Disclosure of Financial Relationships With Any Commercial Interest Name Nature of Financial Commercial Interests
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer SAMO Masterclass 4 th March 2016 Aurelius Omlin Conflicts of interest Advisory Rolle: Astra Zeneca, Astellas, Bayer, Janssen, Pfizer, Sanofi Aventis Research support: TEVA, Janssen
More informationCancer de la prostate métastatique: prise en charge précoce
Cancer de la prostate métastatique: prise en charge précoce Stéphane Oudard, MD, PhD Georges Pompidou Hospital, Oncology Department, Paris, France stephane.oudard@egp.aphp.fr SAGB.CAB.14.08.0382c 3/02/2016
More informationHormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering
> Hormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific
More informationCurrent role of chemotherapy in hormone-naïve patients Elena Castro
Current role of chemotherapy in hormone-naïve patients Elena Castro Spanish National Cancer Research Centre Lugano, 17 October 2017 Siegel, Ca Cancer J Clin,2017 Buzzoni, Eur Urol, 2015 -Aprox 15-20% of
More informationSESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia
SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationADVANCES IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER. ALICIA K. MORGANS, MD, MPH Associate Professor of Medicine Northwestern University, USA
ADVANCES IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER ALICIA K. MORGANS, MD, MPH Associate Professor of Medicine Northwestern University, USA MAY 2018 DISCLAIMER Please note: The views expressed within
More informationChallenging Cases. With Q&A Panel
Challenging Cases With Q&A Panel Case Studies Index Patient #1 Jeffrey Wieder, MD Case # 1 72 year old healthy male with mild HTN Early 2011: Preop bone scan and pelvic CT = no mets Radical prostatectomy
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationAdvanced Prostate Cancer. SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin
Advanced Prostate Cancer SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin aurelius.omlin@kssg.ch Conflicts of Interest Research Support: TEVA, Janssen Advisory Rolle: Astra Zeneca, Astellas,
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationOligometastasis. Körperstereotaxie bei oligo-metastasiertem Prostatakarzinom wann und wie in Kombination mit Systemtherapie?
Körperstereotaxie bei oligo-metastasiertem Prostatakarzinom wann und wie in Kombination mit Systemtherapie? Daniel M. Aebersold 09. Dezember 2016 Oligometastasis JCO, 1995 1 Oligometastasis: Chance for
More informationJoelle Hamilton, M.D.
Joelle Hamilton, M.D. www.urologycentersalabama.com Case Presentation: CRPC, Rising PSA 70 yo healthy, fit, active man post RALP 8 years prior with rising PSA Rising PSA from 0.02 nadir to 3.4 thus ADT
More informationADT vs chemo + ADT as initial treatment for advanced prostate cancer
ADT vs chemo + ADT as initial treatment for advanced prostate cancer By Hussein Khaled Prof. Medical Oncology Cairo University Possible Levels of Prostate Cancer At Diagnosis Local-Regional Disease Spread
More informationUPDATE ON RECENT CUTTING-EDGE TRIALS: TREATMENTS NOW AVAILABLE FOR NEWLY DIAGNOSED mhspc PATIENTS
UPDATE ON RECENT CUTTING-EDGE TRIALS: TREATMENTS NOW AVAILABLE FOR NEWLY DIAGNOSED mhspc PATIENTS Dr. Neal Shore, Carolina Urologic Research Centre, USA Assoc. Prof. Neeraj Agarwal, Huntsman Cancer Institute,
More informationESMO SUMMIT AFRICA Practice changing studies in Prostate Cancer in 2016 and 2017 and cost-effectiveness Ronald de Wit
ESMO SUMMIT AFRICA 2018 Practice changing studies in Prostate Cancer in 2016 and 2017 and cost-effectiveness Ronald de Wit CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche Merck Lilly 14 years of
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in nonorchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationSequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC)
Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC) Amit Bahl Consultant Oncologist Bristol Cancer Institute Clinical Director Spire Specialist Care Centre UK Disclosures Advisory
More informationManagement of Prostate Cancer
Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and
More information2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC
Ronald de Wit Erasmus MC Cancer Institute The Netherlands 2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC Disclosures Sanofi ; research grant support, consultancy and speaker fees Astellas;
More informationGU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer. Dr. Simon Yu Nov 18, 2017
GU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer Dr. Simon Yu Nov 18, 2017 Faculty/Presenter Disclosure Faculty: Dr. Simon Yu Relationships with commercial interests: Grants/Research
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationmcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE
mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE IL CARCINOMA PROSTATICO, UNA MALATTIA ETEROGENEA? RAZIONALE E RISULTATI DEL TRATTAMENTO CHEMIOTERAPICO ASSOCIATO ALL
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer January 13, 2017 Sindu Kanjeekal MD FRCPC Medical Oncology and Hematology Regional Systemic Quality Lead Erie St Clair Adjunct Professor Schulich School of Medicine and University
More informationReview of the Stampede Results. Charles Ryan MD University of California San Francisco
Review of the Stampede Results Charles Ryan MD University of California San Francisco Se#ng and hypothesis Se
More informationFrancesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Chemioterapia: quando e a chi? Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
More informationFocus sulla malattia metastatica ormonosensibile (mhspc) ADT e Terapia ormonale: quando e a chi?
Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Terapia ormonale: quando e a chi? Paolo Andrea Zucali Dipartimento di Oncologia HUMANITAS CANCER CENTER Rozzano - Milano AGENDA Literature
More informationInitial hormone therapy (and more) for metastatic prostate cancer
Initial hormone therapy (and more) for metastatic prostate cancer Silke Gillessen, MD Medical Oncology Kantonsspital St.Gallen Switzerland silke.gillessen@kssg.ch Conflicts of interest Speakers Bureau
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationNOVITÀ IN TEMA DI NEOPLASIA DELLA PROSTATA L ALGORITMO TERAPEUTICO NEL CARCINOMA DELLA PROSTATA METASTATICO SENSIBILE ALLA CASTRAZIONE
NOVITÀ IN TEMA DI NEOPLASIA DELLA PROSTATA L ALGORITMO TERAPEUTICO NEL CARCINOMA DELLA PROSTATA METASTATICO SENSIBILE ALLA CASTRAZIONE S.S. Oncologia Medica Genitourinaria Outline 1. Clinical case 2. Chemotherapy
More informationOpen clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED
More informationSession 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
More informationSecond line hormone therapies. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Second line hormone therapies Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers
More informationUntil 2004, CRPC was consistently a rapidly lethal disease.
Until 2004, CRPC was consistently a rapidly lethal disease. the entry in systemic disease is declared on a an isolated PSA recurrence after local treatment so!!! The management of CRPC and MCRPC is different
More informationIncorporating New Agents into the Treatment Paradigm for Prostate Cancer
Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in non orchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationSYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223
SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223 ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 4-5 October 2018 Disclosures Participation in advisory boards:
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
More informationPlease consider the following information on ZYTIGA (abiraterone acetate). ZYTIGA - Compendia Communication - NCCN LATITUDE and STAMPEDE June 2017
Page 1 of 2 Janssen Scientific Affairs, LLC 1125 Trenton-Harbourton Road PO Box 200 Titusville, NJ 08560 800.526.7736 tel 609.730.3138 fax June 08, 2017 Joan McClure 275 Commerce Drive #300 Fort Washington,
More informationIndex Patients 3& 4. Guideline Statements 10/11/2014. Enzalutamide Reduced the Risk of Death
//4 Prolonged Radiographic Progression-Free Survival Reduced the Risk of Death Overall ITT Population Estimated median rpfs, months (9% CI): : NYR (.8 NYR); placebo:.9 (.7.4) rpfs (%) ( Enza 9 8 7 4 8
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationManagement of castration resistant prostate cancer after first line hormonal therapy fails
Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Rhona McMenemin Consultant in Clinical Oncology The
More informationPLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE. Daan De Maeseneer, Medisch Oncoloog
PLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE Daan De Maeseneer, Medisch Oncoloog 1 Overview DEAT PSA/Tumor Burden METASTASES INITIAL DIAGNOSIS & THERAPY ADT CRP SREs/
More informationCastrate-resistant prostate cancer: Bone-targeted agents. Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Castrate-resistant prostate cancer: Bone-targeted agents Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for: Amgen, Astellas,
More informationNational Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
More informationNon metastatic castrate-resistant prostate cancer (M0 CRPC) Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Non metastatic castrate-resistant prostate cancer (M0 CRPC) Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium for: Amgen, Astellas,
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationProstate Cancer. Dr. Andres Wiernik 2017
Prostate Cancer Dr. Andres Wiernik 2017 Objectives YES!!! 1. Epidemiology 2. Biology or Natural History of Prostate Cancer 3. Treatment NO!!! 1. Prostate Cancer Screening - controversies Which is the most
More informationMetastatic prostate carcinoma. Lee Say Bob July 2017
Metastatic prostate carcinoma Lee Say Bob July 2017 Scenario A 58 year old gentleman presents with PSA 200 ng/ml with hard prostate and bone mets. LUTS but upper tracts are normal with normal RP. history
More informationSergio Bracarda MD, Medical Oncology, Dept. Of Oncology Az. Ospedaliera S. Maria, Terni; Italy. Milano, 2 marzo 2019
Sergio Bracarda MD, Medical Oncology, Dept. Of Oncology Az. Ospedaliera S. Maria, Terni; Italy Milano, 2 marzo 2019 My Disclosure Adv. Board Member for: Pfizer, BMS, Novartis, MSD, Roche, Genentech, Astellas,
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationSTAMPEDE trial (MRC PR08): Arm J overview. Enzalutamide and abiraterone comparison and trial update
STAMPEDE trial (MRC PR08): Arm J overview Enzalutamide and abiraterone comparison and trial update Arm J Hypotheses and rationale STAMPEDE: Hypothesis Will addition of enzalutamide and abiraterone to standard-of-care
More informationCancer de la prostate: best of 2016
Cancer de la prostate: best of 2016 Dr Christophe Massard GR2016, 3 DEC 2016 Disclosure Participation to advisory boards, speaker or investigator for: Amgen, Astellas, Astra Zeneca, Bayer, Celgene, Genentech,
More informationHormonal Manipulations in CRPC. NW Clarke Professor of Urological Oncology Manchester UK
Hormonal Manipulations in CRPC NW Clarke Professor of Urological Oncology Manchester UK Standard Treatment of CRPC Pre 2004 (and in 2013?) PSA progression 99m Tc BS negative CT scan large lymph node component
More informationHormone therapy works best when combined with radiation for locally advanced prostate cancer
Hormone therapy works best when combined with radiation for locally advanced prostate cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Introduction Introduction 1/3 of patients
More information8/31/ ) Intermittent androgen deprivation in androgen-sensitive PCa. 1) Alpharadin (Ra223) in CRPC with bone metastases
Bruce J. Roth, M.D. Clinical Trials: Medivation, Oncogenix 1) Alpharadin (Ra223) in CRPC with bone metastases 2) Enzalutamide (MDV-31) in CRPC and prior docetaxel 3) Abiraterone in chemo-naïve CRPC 4)
More informationASCO 2012 Genitourinary tumors
ASCO 2012 Genitourinary tumors Post ASCO Bern 14-06-2012 Dr. med. Richard Cathomas leitender Arzt Onkologie, KSGR, Chur Renal cell cancer Changes in first line treatment? Prostate cancer 3 positive phase
More informationOpen clinical uro-oncology trials in Canada
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES
More informationIn autopsy, 70% of men >80yr have occult prostate ca
Prostate Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Two randomized trials showed survival benefit of adding docetaxol to ADT in fit man with very high localized disease
More informationNCCN Guidelines for Prostate Cancer V Web teleconference 06/17/16 and 06/30/17
Guideline Page and Request PROS-1 Submission from Myriad Genetic Laboratories, Inc. Request addition of recommendation for genetic risk assessment/testing to the Initial Clinical Assessment algorithm for
More informationProstate Cancer. NCCN Guidelines Version Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines )
NCCN Guidelines Version 1.2016 Prostate NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 2.2017 February 21, 2017 NCCN.org NCCN Guidelines for Patients available at www.nccn.org/patients
More informationNuevas perspectivas en el cáncer de próstata hormono-sensible metastásico Tratamiento actual del cáncer de próstata. Situación de Enzalutamida
Nuevas perspectivas en el cáncer de próstata hormono-sensible metastásico Tratamiento actual del cáncer de próstata. Situación de Enzalutamida Dr Pablo Maroto Hospital Sant Pau Dr Pablo Maroto Hospital
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationFrancesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
Prostata: Oral Communications Emerging strategies and controversial topics in advanced prostate cancer Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
More informationProstate Cancer in comparison to Radiotherapy alone:
Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +
More informationNovel treatment for castration-resistant prostate cancer
Novel treatment for castration-resistant prostate cancer Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Treatment options for patients
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationSUMMARY. 3. Emerging understanding of mechanisms of resistance to current treatments
SUMMARY 1. Discuss the active agents in prostate cancer currently available in Australia 2. Celebrate the growing role for Prostate Medical Oncologists in Multi Disc Teams active treaments overall survival
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Prostate Cancer
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 1.2015 NCCN.org NCCN Guidelines for Patients available at www.nccn.org/patients Continue Version 1.2015, 10/24/14 National Comprehensive
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationDevelopmental Therapeutics for Genitourinary Malignancies
Developmental Therapeutics for Genitourinary Malignancies Russell Szmulewitz, MD April 2018 Disclosure Information 23 rd Annual Developmental Therapeutics Symposium Name of Speaker I have the following
More informationPROSTATE CANCER, Radiotherapy ADVANCES in RADIOTHERAPY for PROSTATE CANCER
PROSTATE CANCER, Radiotherapy ADVANCES in RADIOTHERAPY for PROSTATE CANCER Alberto Bossi Radiotherapy and Oncology Gustave Roussy, Villejuif, France PROSTATE CANCER, Radiotherapy IGRT RT + ADT: short vs
More informationRecent Progress in Management of Advanced Prostate Cancer
Review Article [1] April 15, 2005 By Philip W. Kantoff, MD [2] Androgen-deprivation therapy, usually with combined androgen blockade, is standard initial treatment for advanced prostate cancer. With failure
More informationProstate cancer update: Dr Robert Huddart Cancer Clinic London
Prostate cancer update: 2013 Dr Robert Huddart Cancer Clinic London Recent developments Improved imaging New radiotherapy technologies Radiotherapy for advanced disease Intermittent hormone therapy New
More informationBone-targeted therapies for prostate cancer in Institut Gustave Roussy Villejuif, France
Bone-targeted therapies for prostate cancer in 2012 Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards or speaker for: Amgen, Astellas-Medivation,
More informationProstate Cancer. NCCN Guidelines Version Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines )
NCCN Guidelines Version 1.2016 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 3.2016 NCCN.org NCCN Guidelines for Patients available at www.nccn.org/patients Continue Version
More informationManagement of mcrpc: Hormonal therapy and treatment sequence for CRPC
Management of mcrpc: Hormonal therapy and treatment sequence for CRPC Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Credentials
More informationACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS.
ACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS. ÁLVARO PINTO Servicio de Oncología Médica Hospital Universitario La Paz IdiPAZ, Madrid INTRODUCTION High
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationSIMPOSIO. Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico
SIMPOSIO Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico Definition of Oligometastatic PCa 1-3 synchronous metastases (bone and/or lymph nodes) 2-5 synchronous metastases
More informationThe management and treatment options for secondary bone disease. Dr Jason Lester Clinical Oncologist Velindre Cancer Centre
The management and treatment options for secondary bone disease Dr Jason Lester Clinical Oncologist Velindre Cancer Centre Aims Overview of bone metastases management in castrate-refractory prostate cancer
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationPaul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia
Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy
More informationConvegno Nazionale AIOM Giovani 2016: News in Oncology. Daniele Alesini. Istituto Nazionale dei Tumori Regina Elena
Convegno Nazionale AIOM Giovani 2016: News in Oncology Daniele Alesini Istituto Nazionale dei Tumori Regina Elena Something Old Something New Something Borrowed Something Blue DOCETAXEL: BACK AND FORTH
More informationAmerican Urological Association (AUA) Guideline
1 Approved by the AUA Board of Directors May 2018 Authors disclosure of potential conflicts of interest and author/staff contributions appear at the end of the article. 2018 by the American Urological
More informationBoard Review 2017: Prostate Cancer. Dana Rathkopf, MD Associate Attending
Board Review 2017: Prostate Cancer Dana Rathkopf, MD Associate Attending www.mskcc.org The Paradox of Prostate Cancer High prevalence in the general population: over diagnosis of clinically insignificant
More information